Breaking News, Financial News

Financial Report: Lilly 3Q08

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lilly 3Q Revenues: $5.2 billion (+14%) 3Q Loss: $465.6 million (earnings were $926.3 million in 3Q07) YTD Revenues: $15.2 billion (+13%) YTD Earnings: $1.6 billion (-26%) Comments: Zyprexa sales were $1.2 billion in the quarter (+2%). Cymbalta sales were $716.4 million (+40%). Gemzar sales were $440.2 million (+12%). Humalog sales were up 19% to $432.6 million. Cialis sales were $376.6 million (+21%). Alimta sales were $313.9 million (46%). Strattera sales were $149.5 million (+15...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters